Biohacking Kompakt

Tip · Breathing

Buteyko breathing for people with allergies & asthma

In asthma, studies show fewer symptoms and less reliever medication – lung function itself does not change.

Buteyko breathing is a form of breathing retraining towards calm, shallow nasal breathing with short pauses. It is included here because it is one of the few techniques of its kind that have made it into an international medical guideline — and because that guideline also states what it cannot do.

In short

In diagnosed asthma, Buteyko works on symptoms and reliever medication, shown repeatedly in controlled trials. In a meta-analysis of seven randomized trials, Buteyko added to standard therapy improved asthma control with a standardized mean difference of −0.33. In the study with a genuine placebo device, the use of reliever medication fell by two puffs per day after six months. What does not change is objective disease activity: according to the guideline, at the highest level of evidence, lung function and exacerbation risk remain unaffected. No controlled studies could be found for hay fever and panic attacks.

What is behind it

The Buteyko theory holds that chronic hyperventilation lowers CO2 in the blood too far and thereby triggers asthma symptoms; the exercise is meant to raise CO2 again. What is practiced is calm breathing through the nose with short voluntary breath holds, in the studies twice daily over months.

The international asthma guideline GINA puts it this way in 2025: breathing exercises may be considered as an adjunct to conventional asthma therapy for symptoms and quality of life, but they do not improve lung function and do not reduce exacerbation risk — evidence A. Benefit and limit thus stand in the same sentence.

How it works

The first part of the theory is measurable: a meta-analysis of eight studies on breathing retraining in asthma found a significant large effect on end-tidal CO2 after treatment and at 3 and 6 months afterwards.

The second part — that precisely this rise in CO2 produces the clinical benefit — has been tested directly, and the result was mixed. Compared with simply breathing slowly, capnometry-assisted training achieved larger rises in pCO2 (d = 1.45 versus 0.64) and a greater reduction in symptoms at follow-up. Most of the improvement, however, occurred in both groups. GINA accordingly states that the perceived benefit may largely be due to relaxation, voluntary reduction of medication or greater patient involvement.

What improves and what does not

Symptom scores, asthma control and the use of reliever spray and inhaled corticosteroid improve. FEV1, bronchial hyperresponsiveness, exacerbation risk and exhaled nitric oxide do not improve. Someone who feels better and needs less spray does not have less asthma as a result.

What is well supported

A meta-analysis of randomized trials with seven RCTs for asthma control found a standardized mean difference of −0.33 for Buteyko added to standard therapy (95% CI −0.54 to −0.13, p = 0.001, I² = 0%), −0.28 in adults and −0.48 in children and adolescents; no adverse events were reported. In the study with the most rigorous design — 90 asthma patients, a genuine placebo device in the comparison arm, six months, 69 of 90 (78%) completed it — the symptom score changed by a median of −3 under Buteyko versus 0 under placebo (p = 0.003), and reliever medication use fell by two puffs per day (p = 0.005). A more recent study with two groups of 30 patients each over 3 months confirms the pattern: the use of β2-agonists and inhaled corticosteroids each fell by about 20%.

What the studies show

With a genuine placebo device (Cooper et al. 2003)

90 asthma patients on inhaled corticosteroid, three arms: eucapnic Buteyko breathing, a breathing device mimicking pranayama and a placebo device, each for six months twice daily at home. Primary endpoints were symptom scores and the change in the methacholine dose that triggers a 20% fall in FEV1. Symptoms improved markedly and reliever medication fell — but there was no difference in bronchial reactivity, FEV1, exacerbations or steroid reduction.

Is it the technique? (Slader et al. 2006)

Double-blind design with 57 patients, randomized to shallow nasal breathing or to nonspecific upper-body exercises, both taught by video, over 30 weeks. No clinically meaningful differences between the groups, neither at week 12 nor at week 28. Across both groups, however, reliever medication use fell by 86% and the corticosteroid dose by 50%.

The test of the CO2 hypothesis (Ritz et al. 2014)

120 asthma patients, randomized to capnometry-assisted breathing training to raise CO2 or to training in slower breathing, over 4 weeks. Both groups improved in 17 of 21 clinical measures (81.0%), including asthma control (d = 0.81) and peak flow variability (d = 0.54); most improvements lasted over 6 months.

The largest study in this family (Bruton et al. 2018)

655 patients from 34 British general practices, randomized in a 2:1:2 ratio to a self-guided DVD with an accompanying booklet, three face-to-face physiotherapy sessions or usual care, over 12 months. Quality of life score after 12 months: DVD 5.40 versus usual care 5.12, adjusted difference 0.28; face-to-face sessions 5.33, adjusted difference 0.24. No significant differences in FEV1 or FeNO.

What the studies do not show

The specific technique has not been shown to be better than nonspecific exercises. In the only double-blind head-to-head comparison, shallow nasal breathing did not differ from nonspecific upper-body exercises; reliever medication fell by 86% in both groups, the corticosteroid dose by 50% in both. Lung function does not change: FEV1 and methacholine challenge remained unchanged. Quality of life does not consistently improve either — in the Buteyko meta-analysis there was no overall benefit (SMD 0.13; 95% CI −0.23 to 0.49; p = 0.47), only in the subgroup of children and adolescents (SMD 0.44).

Two claims from the existing entry do not hold up on checking. No controlled studies on the Buteyko method could be found for hay fever and panic attacks; what exists is research on capnometry-assisted breathing training in asthma patients with heightened anxiety — a different intervention with a device and instruction. And for the widespread dosing claim of 3 to 5 second pauses and more than 10 minutes a day, no study source could be found: the studies describe their dosing as twice daily over months, without a pause length in seconds.

How to do it

In the studies, people practiced twice daily at home over 3 to 8 months: six months in Cooper et al., 30 weeks in Slader et al., three months in Vagedes et al. with the voluntary breath hold as the primary endpoint. The most important practical finding comes from the largest study: a DVD with a printed accompanying booklet for self-study worked just as well as three face-to-face physiotherapy sessions, and both better than usual care. GINA explicitly notes that the cost of some commercial programs is a limitation and points to freely available materials.

Safety

The direct safety data are unremarkable: the Buteyko meta-analysis of seven RCTs reports no adverse events, and neither does a systematic review of 73 randomized controlled trials with 5,479 participants. The real risk lies in replacing medication. The best-replicated effect of the method is that people take less reliever spray and less inhaled corticosteroid while objective disease activity does not change. Reducing maintenance therapy therefore belongs in a doctor’s hands and should be tied to monitoring of lung function; this is exactly how the studies proceeded. In acute breathlessness, reliever medication is the treatment — none of these techniques has been tested as a treatment for attacks. There are no data for pregnant women or for COPD, and nasal breathing during physical exertion is explicitly advised against in COPD.

BK-Score Thin human evidence

Human evidence5
Mechanism4
Safety data7
Hype gap4
Track record of use7

Controlled studies in asthma show fewer symptoms and less reliever medication – objective lung function, however, does not change. The rise in CO2 through breathing retraining is measurable and contributes its own share to the effect; the broader Buteyko assumption that chronic hyperventilation is the cause of asthma, by contrast, is not supported.

The score rates the state of knowledge, not the effect. “Safety data 9” means well studied – not harmless.
Subjective assessment by Biohacking Kompakt based on published scoring rules – not a scientific rating and not a medical recommendation. Rules and all ratings (German)

Frequently asked questions about Buteyko breathing for people with allergies & asthma

Does Buteyko work for asthma?

For symptoms and reliever medication, yes, and this has been shown repeatedly in controlled trials. In a meta-analysis of seven randomized trials, Buteyko added to standard therapy improved asthma control with a standardized mean difference of −0.33. In the study with a genuine placebo device, reliever medication use fell by two puffs per day after six months.

Does it also improve my lung function?

No. This is the best-established negative finding on this topic. The international asthma guideline assigns it the highest level of evidence: breathing exercises do not improve lung function and do not reduce exacerbation risk. In the study with methacholine challenge, bronchial hyperresponsiveness also remained unchanged.

Is the Buteyko technique itself what matters, or will any exercise do?

The only double-blind head-to-head comparison speaks against the technique as such. Shallow nasal breathing did not perform better than nonspecific upper-body exercises, and in both groups reliever medication use fell by 86 percent. The guideline concludes from this that the benefit may largely be due to relaxation, voluntary reduction of medication and greater involvement in one’s own treatment.

Is the CO2 theory behind Buteyko correct?

Partly. That breathing retraining measurably raises end-tidal CO2 is supported by meta-analysis. In the study that specifically pitted raising CO2 against simply breathing slowly, the CO2 group had advantages of its own: a larger rise in CO2, lower airway impedance, less strain during the challenge test and a greater reduction in symptoms over time. Most of the improvement, however, occurred in both groups.

Does Buteyko help against hay fever or panic attacks?

No controlled studies on this could be found. There is research on capnometry-assisted breathing training in asthma patients with heightened anxiety, but that is a different intervention with a device and instruction, not Buteyko. The claims about hay fever and panic attacks are currently unsupported.

May I use it to reduce my asthma spray?

Only with medical supervision. Reducing is precisely the most striking effect of the method, and at the same time objective disease activity does not change and, according to the guideline, exacerbation risk does not fall. In the studies, reduction steps were defined, monitored and accompanied by lung function measurements.

Related

Sources

Open in the database – with all tips, filters and BK-Score (German app)

Information only, not medical advice and not a usage recommendation. If you have pre-existing conditions, and before making major changes, consult a doctor. Last updated: 2026-10-06.